Table 3.
A Cox regression model was fitted for all eligible patients to evaluate the impact of main effect on overall survival since 30-d post relapse, while controlling for other risk factors.
| Cox Model Estimates (N=215) | ||||
|---|---|---|---|---|
| Parameter | N (N Event) | HR (%95 CI) | P-value | Overall P-value |
| Disease status prior to HCT | ||||
| CP1 (reference) | 69 (22) | 1.00 | <.001 | |
| AP | 35 (16) | 1.60 (0.83, 3.09) | 0.157 | |
| BP | 25 (21) | 5.51 (2.93, 10.37) | <.001 | |
| CP2+ | 52 (31) | 2.64 (1.46, 4.79) | 0.001 | |
| Hematologic CR | 34 (18) | 1.90 (0.94, 3.86) | 0.075 | |
| Main effect | ||||
| TKI + DLI (reference) | 48 (24) | 1.00 | 0.011 | |
| DLI but no TKI | 39 (24) | 2.28 (1.23, 4.24) | 0.009 | |
| TKI but no DLI | 128 (60) | 1.06 (0.65, 1.72) | 0.813 | |
| Post-HCT maintenance TKI Therapy | ||||
| Yes (reference) | 58 (20) | 1.00 | 0.007 | |
| No | 157 (88) | 2.00 (1.21, 3.31) | 0.007 | |
| Year of Transplant | ||||
| 2002–2007 (reference) | 110 (49) | 1.00 | 0.026 | |
| 2008–2014 | 105 (59) | 1.68 (1.06, 2.64) | 0.026 |
*
In addition, the other variables we considered but were not selected are age group, gender, country, KPS, ATG/Alemtuzumab, time from transplant to relapse, TBI given, conditioning intensity, recipient CMV status, donor type, graft source, GVHD Prophylaxis and GVHD prior to the landmark analysis.